{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pembrolizumab&page=40", "query": { "intervention": "pembrolizumab", "page": 40 }, "page_size": 10 }, "pagination": { "page": 40, "page_size": 10, "total_count": 1847, "total_pages": 185, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pembrolizumab&page=41&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pembrolizumab&page=39&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T09:26:59.658Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04526691", "title": "Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced or Metastatic NSCLC" ], "interventions": [ { "name": "Datopotamab deruxtecan", "type": "DRUG" }, { "name": "KEYTRUDA®", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 145, "start_date": "2020-09-15", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-10-31T09:26:59.658Z", "location_count": 9, "location_summary": "Scottsdale, Arizona • Duarte, California • Washington D.C., District of Columbia + 5 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04526691" }, { "nct_id": "NCT03546582", "title": "SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma (HNSCC)" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Stereotactic Body Radiation Therapy (SBRT)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "RTOG Foundation, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 86, "start_date": "2018-11-14", "completion_date": "2029-07", "has_results": false, "last_update_posted_date": "2026-01-20", "last_synced_at": "2026-10-31T09:26:59.658Z", "location_count": 15, "location_summary": "Tucson, Arizona • Tampa, Florida • Weston, Florida + 12 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tampa", "state": "Florida" }, { "city": "Weston", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03546582" }, { "nct_id": "NCT03924856", "title": "Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])", "type": "PROCEDURE" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 907, "start_date": "2019-06-13", "completion_date": "2026-05-18", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-31T09:26:59.658Z", "location_count": 24, "location_summary": "La Jolla, California • Santa Monica, California • Washington D.C., District of Columbia + 21 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" }, { "city": "Fort Wayne", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03924856" }, { "nct_id": "NCT03567720", "title": "Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Triple Negative Breast Cancer" ], "interventions": [ { "name": "tavokinogene telseplasmid", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Immunopulse", "type": "DEVICE" }, { "name": "nab paclitaxel", "type": "DRUG" }, { "name": "gemcitabine plus carboplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DEVICE", "DRUG" ], "sponsor": "OncoSec Medical Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2018-10-11", "completion_date": "2024-09", "has_results": false, "last_update_posted_date": "2023-06-01", "last_synced_at": "2026-10-31T09:26:59.658Z", "location_count": 10, "location_summary": "Tucson, Arizona • La Jolla, California • Palo Alto, California + 7 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03567720" }, { "nct_id": "NCT02982720", "title": "Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Cholangiocarcinoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Sylatron", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aiwu Ruth He, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2017-07-05", "completion_date": "2018-02-09", "has_results": true, "last_update_posted_date": "2022-02-16", "last_synced_at": "2026-10-31T09:26:59.658Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02982720" }, { "nct_id": "NCT03486873", "title": "Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Solid Tumors", "Hematologic Malignancies" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Standard of Care (SOC)", "type": "DRUG" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "MK-4280", "type": "DRUG" }, { "name": "MK-4280A", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab (+) Berahyaluronidase alfa", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3500, "start_date": "2018-08-21", "completion_date": "2043-08-04", "has_results": false, "last_update_posted_date": "2026-10-29", "last_synced_at": "2026-10-31T09:26:59.658Z", "location_count": 65, "location_summary": "Tucson, Arizona • Bakersfield, California • Fresno, California + 56 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03486873" }, { "nct_id": "NCT03910660", "title": "A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Cancer", "Neuroendocrine Tumors", "Small Cell Carcinoma" ], "interventions": [ { "name": "BXCL701 plus Pembrolizumab", "type": "DRUG" }, { "name": "BXCL701 monotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioXcel Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 98, "start_date": "2019-02-12", "completion_date": "2025-08-31", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-10-31T09:26:59.658Z", "location_count": 9, "location_summary": "San Francisco, California • Denver, Colorado • New Haven, Connecticut + 6 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03910660" }, { "nct_id": "NCT03564691", "title": "Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "MK-4830", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "MK-4830A", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 470, "start_date": "2018-07-11", "completion_date": "2025-09-26", "has_results": false, "last_update_posted_date": "2025-10-07", "last_synced_at": "2026-10-31T09:26:59.658Z", "location_count": 9, "location_summary": "San Francisco, California • Detroit, Michigan • St Louis, Missouri + 6 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03564691" }, { "nct_id": "NCT03255018", "title": "Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Hodgkin Lymphoma", "Lymphoma", "Diffuse Large B-Cell Lymphoma", "Gray-zone Lymphoma", "Primary Central Nervous System Lymphoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2018-02-15", "completion_date": "2023-06-29", "has_results": true, "last_update_posted_date": "2023-11-28", "last_synced_at": "2026-10-31T09:26:59.658Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03255018" }, { "nct_id": "NCT05270213", "title": "Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer" ], "interventions": [ { "name": "RBS2418", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Other approved anti-cancer therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Riboscience, LLC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 164, "start_date": "2022-07-11", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2025-12-19", "last_synced_at": "2026-10-31T09:26:59.658Z", "location_count": 14, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Palo Alto, California + 11 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Newark", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT05270213" } ] }